Sign In
29 Aug 2008 07:00
PuriCore plc
("PuriCore" or the "Company")
Total Voting Rights
MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 29 August 2008 - PuriCore (LSE: PURI), the life sciences company focused on developing and commercialising proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment, announces that for the purposes of Rule 5.6 of the Disclosure and Transparency Rules, the Company's issued share capital consists of 216,499,628 Ordinary Shares of 1 pence each.
PuriCore does not hold any shares in Treasury.
The total number of voting rights in PuriCore plc is therefore 216,499,628.
The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, PuriCore plc, under the Disclosure and Transparency Rules.
Enquiries:
|
Ben Brewerton |
Greg Bosch, CEO |
|
Susan Quigley |
Keith A. Goldan, CFO |
|
Financial Dynamics |
PuriCore |
|
+44 (0) 20 7831 3113 |
+1 484 321 2700 |
About PuriCore
PuriCore plc (LSE: PURI) is a life sciences company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore targets markets that depend upon controlling contamination, including food safety in retail and foodservice, medical device disinfection, and wound therapy. The Company's patented, proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, which is highly effective in killing bacteria, viruses, and fungal spores, simply from water, common salt, and electricity. Hypochlorous acid is proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of M. tuberculosis, MRSA, E.coli, Norovirus, H5N1 Avian Influenza, HIV, Salmonella, Polio Virus, Helicobater pylori, and Legionella. PuriCore is headquartered in Malvern, Pennsylvania, with offices in Stafford, UK.
To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.
To subscribe to our investor news alerts, visit http://investor.puricore.com.
Follow the stocks
